SCHEMBL2907264

SCHEMBL2907264

Fc1ccc(-c2cc(Cl)ncn2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.44
ALDH1A1 P00352 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
CLK4 Q9HAZ1 2/20 0.44
MEN1 O00255 1/20 0.44
USP2 O75604 1/20 0.44
TP53 P04637 1/20 0.44
GLA P06280 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
ALOX15 P16050 1/20 0.44
MAPK1 P28482 1/20 0.44
KMT2A Q03164 1/20 0.44
HSD17B10 Q99714 1/20 0.44
KMO O15229 5/20 0.42
FAAH O00519 1/20 0.41
GRM5 P41594 2/20 0.39
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1257940 0.83 KMO (0.58) CLK4MEN1KMT2AKMOFAAH
SCHEMBL19244911 0.80 KMO (0.46) ALDH1A1CLK4MEN1TP53KMT2A
SCHEMBL3405923 0.80 KMO (0.49) ALDH1A1CLK4MEN1TP53CYP3A4
SCHEMBL20137316 0.80 ASIC3 (0.55) CYP1A2ALDH1A1CYP2C9CYP2C19MEN1
SCHEMBL3406220 0.80 KMO (0.46) CLK4KMOMAP4K4AAK1CDC7
SCHEMBL15339601 0.80 KDM4E (0.46) ALDH1A1CLK4MEN1KMT2AKMO
SCHEMBL605004 0.79 ABL1 (0.50) FAAHAAK1
SCHEMBL4430566 0.79 KMO (0.58) CLK4MEN1KMT2AKMOGRM5
SCHEMBL632053 0.79 ASIC3 (0.59) CYP1A2ALDH1A1CYP2C9CYP2C19CLK4
SCHEMBL29392239 0.79 ASIC3 (0.59) CYP1A2ALDH1A1CYP2C9CYP2C19CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106632488-A Sterically-hindered pyrimidine iridium complex phosphorescence material and preparation method thereof 安徽工业大学 2017-05-10 CN disclosed
US-20130338147-A1 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES INGENIUM PHARMACEUTICALS GMBH (DE) 2013-12-19 US disclosed
US-8507498-B2 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases INGENIUM PHARMACEUTICALS GMBH (DE) 2013-08-13 US disclosed
US-8507498-B2 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases INGENIUM PHARMACEUTICALS GMBH (DE) 2013-08-13 US disclosed
EP-2137166-B1 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES INGENIUM PHARMACEUTICALS GMBH (DE) 2012-05-30 EP disclosed
US-20110306602-A1 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES ASTRAZENECA AB (SE) 2011-12-15 US disclosed
US-20110306602-A1 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES ASTRAZENECA AB (SE) 2011-12-15 US disclosed
US-20110306602-A1 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES ASTRAZENECA AB (SE) 2011-12-15 US disclosed
EP-1989194-B1 CYCLIC SULFONES USEFUL AS BACE INHIBITORS NOVARTIS AG (CH) 2010-08-25 EP disclosed
US-20100144741-A1 ETHANOLAMINE DERIVATIVES USEFUL AS BACE INHIBITORS FREDERIKSEN MATHIAS 2010-06-10 US disclosed
US-7291730-B2 Pyrimidine compounds and their use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-11-06 US disclosed
US-7291730-B2 Pyrimidine compounds and their use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-11-06 US disclosed
WO-2007093621-A1 CYCLIC SULFONES USEFUL AS BACE INHIBITORS NOVARTIS AG (CH) 2007-08-23 WO disclosed
US-20050107609-A1 Pyrimidine compounds and their use SUMITOMO CHEMICAL COMPANY 2005-05-19 US disclosed
US-6838463-B2 Pyrimidine compounds and their use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-01-04 US disclosed
EP-1366026-B1 PYRIMIDINE COMPOUNDS AND THEIR USE AS PESTICIDES SUMITOMO CHEMICAL CO (JP) 2004-12-01 EP disclosed
US-20040077669-A1 Pyrimidine compounds and their use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-04-22 US disclosed
CN-1478082-A Pyrimidine compound and application thereof ס�ѻ�ѧ��ҵ��ʽ���� 2004-02-25 CN disclosed
EP-1366026-A2 PYRIMIDINE COMPOUNDS AND THEIR USE SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2003-12-03 EP disclosed
WO-2002024663-A2 PYRIMIDINE COMPOUNDS AND THEIR USE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338147-A1 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES CDK2, CDK6, CDK5 CYP1A2 3578/4885ALDH1A1 3032/4885CYP2C9 3879/4885
US-20110306602-A1 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES CDK6, CDK2, CDK1 CYP1A2 2965/4885ALDH1A1 2564/4885CYP2C9 3127/4885
US-20050107609-A1 Pyrimidine compounds and their use TYMP, TYMS, UMPS CYP1A2 361/4885ALDH1A1 783/4885CYP2C9 320/4885
US-20040077669-A1 Pyrimidine compounds and their use TYMP, TYMS, DPYD CYP1A2 647/4885ALDH1A1 654/4885CYP2C9 334/4885
US-20100144741-A1 ETHANOLAMINE DERIVATIVES USEFUL AS BACE INHIBITORS BACE1, BACE2, APP CYP1A2 1730/4885ALDH1A1 447/4885CYP2C9 2013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.